The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics

Britten K. Gordon, Jennifer A. Woyach

Research output: Contribution to journalReview articlepeer-review

Abstract

Treatment of chronic lymphocytic leukemia (CLL) has been revolutionized with the introduction of small molecule inhibitors targeting both the B-cell receptor (BCR) signaling pathway and B-cell lymphoma-2 (BCL-2) family of proteins. Inhibitors of Bruton’s tyrosine kinase (BTK) and the BH3 mimetic venetoclax are bothcurrently used as the standard of care for patients in the frontline and relapsed/refractory setting of CLL. With the clinical success of both these classes of therapies, sequencing of these agents has become a major challenge in treatment of CLL. In this review we will discuss the current data available for both classes of agents in the front-line and relapsed/refractor setting, considerations when giving these agents, and how we can continue to improve the treatment landscape for CLL.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - 2025

Keywords

  • BTK inhibitors
  • CLL
  • venetoclax

Fingerprint

Dive into the research topics of 'The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics'. Together they form a unique fingerprint.

Cite this